Skip to main content

Table 3 Other medication use in the 6 months prior to and after tofacitinib initiation

From: Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis

 

Overall

Biologic-naïve

1 prior biologic

 ≥ 2 prior biologics

N = 225

N = 43

N = 92

N = 90

6-month baseline

6-month follow-up

6-month baseline

6-month follow-up

6-month baseline

6-month follow-up

6-month baseline

6-month follow-up

5-ASA, n (%)

112 (49.8)

70 (31.1)

25 (58.1)

16 (37.2)

49 (53.3)

30 (32.6)

38 (42.2)

24 (26.7)

Immunomodulator, n (%)

68 (30.2)

21 (9.3)

3 (7.0)

4 (9.3)

31 (33.7)

14 (15.2)

34 (37.8)

3 (3.3)

Oral corticosteroids, n (%)a

148 (65.8)

93 (41.3)

32 (74.4)

10 (23.3)

56 (60.9)

39 (42.4)

60 (66.7)

44 (48.9)

  Daily dose, mg/day, mean (SD)b

31.5 (16.2)

28.2 (13.5)

30.1 (18.2)

22.5 (17.9)

33.6 (19.7)

26.6 (14.1)

30.4 (10.6)

30.9 (11.3)

  1. Baseline was defined as the 6 months prior to index date. Follow-up period was 6 months following the index date
  2. 5-ASA, 5-aminosalicylates; n, number of patients in the specified category; N, number of patients in the treatment group; TNFi, tumour necrosis factor inhibitor
  3. aBased on pharmacy claims only
  4. bPrednisone equivalent